Klein R J, Friedman-Kien A E, DeStefano E
Antimicrob Agents Chemother. 1979 May;15(5):723-9. doi: 10.1128/AAC.15.5.723.
Acycloguanosine (ACG) was able to prevent the fatal outcome of herpes simplex virus-induced skin infections of the lumbosacral or orofacila area in hairless mice. Topical ACG treatment was more effective than systemic treatment in preventing the evolution of skin lesions. Acute ganglionic infections in the trigeminal ganglia were prevented by ACG, and latent ganglionic infections did not become established when the ACG treatment was initiated 3 h after infection. Serum antibody titers were, on the average, eight times higher in mice which developed latent ganglionic infections after ACG treatment than in mice without evidence of herpes simplex virus latency in ganglia. Reinoculation of ACG-treated mice at a site different from that of the primary inoculation did not lead to the establishment of a second latent infection with the homologous virus type when a latent infection was already present. In mice without evidence of latent infection after the primary inoculation, a latent infection at the site of reinoculation became established in 25% of the animals.
阿昔洛韦(ACG)能够预防单纯疱疹病毒引起的无毛小鼠腰骶部或口面部皮肤感染的致命后果。在预防皮肤病变发展方面,局部应用ACG治疗比全身治疗更有效。ACG可预防三叉神经节的急性神经节感染,并且在感染后3小时开始ACG治疗时,潜伏性神经节感染不会形成。平均而言,ACG治疗后发生潜伏性神经节感染的小鼠血清抗体滴度比神经节无单纯疱疹病毒潜伏迹象的小鼠高8倍。当已经存在潜伏感染时,在与初次接种部位不同的部位再次接种ACG治疗的小鼠,不会导致同源病毒型的第二次潜伏感染。在初次接种后无潜伏感染迹象的小鼠中,25%的动物在再次接种部位形成了潜伏感染。